These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 35544051)

  • 61. Dissolvable Microneedle Patches to Enable Increased Access to Vaccines against SARS-CoV-2 and Future Pandemic Outbreaks.
    O'Shea J; Prausnitz MR; Rouphael N
    Vaccines (Basel); 2021 Apr; 9(4):. PubMed ID: 33915696
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Live-Attenuated VEEV Vaccine Delivered by iDNA Using Microneedles Is Immunogenic in Rabbits.
    Tretyakova I; Tomai M; Vasilakos J; Pushko P
    Front Trop Dis; 2022 Mar; 3():. PubMed ID: 37854093
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Evaluation of the self-administration potential of high-density microarray patches to human skin: A preliminary study.
    Baker B; Hacker E; Siller G; Lee M; Mursaliyev N; Forster A
    Hum Vaccin Immunother; 2023 Dec; 19(1):2189409. PubMed ID: 36949009
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Tolerability of a piezoelectric microneedle electroporator in human subjects.
    Lu CY; Rohilla P; Felner EI; Byagathvalli G; Azizoglu E; Bhamla MS; Prausnitz MR
    Bioeng Transl Med; 2024 Jul; 9(4):e10662. PubMed ID: 39036075
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Spatial tumor biopsy with fluorescence PCR microneedle array.
    Zhang X; Chen G; Wang Y; Zhao Y
    Innovation (Camb); 2024 Jan; 5(1):100538. PubMed ID: 38089565
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Post-COVID-19 vaccine acute encephalitis in an adult patient: A case report and literature review.
    Pakfetrat M; Malekmakan L; Najafi B; Zamani T; Mashayekh M
    Clin Case Rep; 2023 Feb; 11(2):e6915. PubMed ID: 36789322
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Correction to: Evaluating Islatravir Administered Via Microneedle Array Patch for Long-Acting HIV Pre-exposure Prophylaxis Using Physiologically Based Pharmacokinetic Modelling.
    Kinvig H; Cottura N; Lloyd A; Frivold C; Mistilis J; Jarrahian C; Siccardi M
    Eur J Drug Metab Pharmacokinet; 2023 Jan; 48(1):119. PubMed ID: 36517732
    [No Abstract]   [Full Text] [Related]  

  • 68. Addressing vaccine-preventable encephalitis in vulnerable populations: Erratum.
    Curr Opin Neurol; 2024 Feb; 37(1):95-96. PubMed ID: 38193503
    [No Abstract]   [Full Text] [Related]  

  • 69. Author Correction: Porous microneedle patch with sustained delivery of extracellular vesicles mitigates severe spinal cord injury.
    Fang A; Wang Y; Guan N; Zuo Y; Lin L; Guo B; Mo A; Wu Y; Lin X; Cai W; Chen X; Ye J; Abdelrahman Z; Li X; Zheng H; Wu Z; Jin S; Xu K; Huang Y; Gu X; Yu B; Wang X
    Nat Commun; 2023 Aug; 14(1):4603. PubMed ID: 37528087
    [No Abstract]   [Full Text] [Related]  

  • 70. Encephalitis after COVID-19 vaccination.
    Lopez-Gonzalez R; Otalvaro-Rendon MA; Quintero-Gutierrez L
    Neurologia (Engl Ed); 2024 Feb; ():. PubMed ID: 38387780
    [No Abstract]   [Full Text] [Related]  

  • 71. Safety, Tolerability, and Immunogenicity of Measles and Rubella Vaccine Delivered with a High-Density Microarray Patch: Results from a Randomized, Partially Double-Blinded, Placebo-Controlled Phase I Clinical Trial.
    Baker B; Bermingham IM; Leelasena I; Hickling J; Young PR; Muller DA; Forster AH
    Vaccines (Basel); 2023 Nov; 11(11):. PubMed ID: 38006057
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Current Status of Microneedle Array Technology for Therapeutic Delivery: From Bench to Clinic.
    Chakraborty C; Bhattacharya M; Lee SS
    Mol Biotechnol; 2023 Nov; ():. PubMed ID: 37987985
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Immunogenicity, safety, usability and acceptability of microarray patches for vaccination: a systematic review and meta-analysis.
    Berger MN; Mowbray ES; Farag MWA; Mathieu E; Davies C; Thomas C; Booy R; Forster AH; Skinner SR
    BMJ Glob Health; 2023 Oct; 8(10):. PubMed ID: 37827725
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Skin-Based Vaccination: A Systematic Mapping Review of the Types of Vaccines and Methods Used and Immunity and Protection Elicited in Pigs.
    Có-Rives I; Chen AY; Moore AC
    Vaccines (Basel); 2023 Feb; 11(2):. PubMed ID: 36851328
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Local Response and Barrier Recovery in Elderly Skin Following the Application of High-Density Microarray Patches.
    Iredahl F; Muller DA; Togö T; Jonasson H; Baker B; Anderson CD; Henricson J
    Vaccines (Basel); 2022 Apr; 10(4):. PubMed ID: 35455332
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Opportunities and challenges for commercializing microarray patches for vaccination from a MAP developer's perspective.
    Forster A; Junger M
    Hum Vaccin Immunother; 2022 Nov; 18(4):2050123. PubMed ID: 35356872
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Safety and dose-sparing effect of Japanese encephalitis vaccine administered by microneedle patch in uninfected, healthy adults (MNA-J): a randomised, partly blinded, active-controlled, phase 1 trial.
    Iwata H; Kakita K; Imafuku K; Takashima S; Haga N; Yamaguchi Y; Taguchi K; Oyamada T
    Lancet Microbe; 2022 Feb; 3(2):e96-e104. PubMed ID: 35544051
    [TBL] [Abstract][Full Text] [Related]  

  • 78. The safety, immunogenicity, and acceptability of inactivated influenza vaccine delivered by microneedle patch (TIV-MNP 2015): a randomised, partly blinded, placebo-controlled, phase 1 trial.
    Rouphael NG; Paine M; Mosley R; Henry S; McAllister DV; Kalluri H; Pewin W; Frew PM; Yu T; Thornburg NJ; Kabbani S; Lai L; Vassilieva EV; Skountzou I; Compans RW; Mulligan MJ; Prausnitz MR;
    Lancet; 2017 Aug; 390(10095):649-658. PubMed ID: 28666680
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Safety and immunogenicity of a purified inactivated Zika virus vaccine candidate in adults primed with a Japanese encephalitis virus or yellow fever virus vaccine in the USA: a phase 1, randomised, double-blind, placebo-controlled clinical trial.
    Koren MA; Lin L; Eckels KH; De La Barrera R; Dussupt V; Donofrio G; Sondergaard EL; Mills KT; Robb ML; Lee C; Adedeji O; Keiser PB; Curley JM; Copeland NK; Crowell TA; Hutter JN; Hamer MJ; Valencia-Ruiz A; Darden J; Peel S; Amare MF; Mebrahtu T; Costanzo M; Krebs SJ; Gromowski GD; Jarman RG; Thomas SJ; Michael NL; Modjarrad K
    Lancet Infect Dis; 2023 Oct; 23(10):1175-1185. PubMed ID: 37390836
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial.
    Wu Z; Hu Y; Xu M; Chen Z; Yang W; Jiang Z; Li M; Jin H; Cui G; Chen P; Wang L; Zhao G; Ding Y; Zhao Y; Yin W
    Lancet Infect Dis; 2021 Jun; 21(6):803-812. PubMed ID: 33548194
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.